The Leukemia & Lymphoma Society® is the largest voluntary health organization dedicated to funding research, finding cures and ensuring access to treatments for blood cancer patients.
The Leukemia & Lymphoma Society is at the forefront of the fight to cure cancer. We are the largest nonprofit dedicated to creating a world without blood cancers. Since 1949, we’ve invested more than $1.2 billion in groundbreaking research, pioneering many of today’s most innovative approaches.
Cancer is a heck of an opponent. It’s a bully. But we aren’t afraid of a fight. It’s elusive. But our focus never fades. It’s deadly. But we are known cancer killers. Since our beginning, we’ve pioneered groundbreaking research that leads us to believe we will find the cures for cancer in our blood. We were born to defeat this opponent. We are The Leukemia & Lymphoma Society. Beating cancer is in our blood.
What Are Blood Cancers?
Approximately every three minutes, a person in the United States is diagnosed with a blood cancer. Every nine minutes, someone dies from it. An estimated 173,000 Americans will be diagnosed with leukemia, lymphoma or myeloma in 2018, and more than 58,000 Americans will die from these diseases.
There are three main types of blood cancers: leukemia, lymphoma and myeloma. In addition, there are other types that affect the blood and bone marrow, including myelodysplastic syndromes and myeloproliferative neoplasms.
While there are three main types of blood cancer, each cancer is unique and there are many different subtypes. This is why new developments in precision medicine treatments are targeting cancers at the molecular level to ensure patients receive the right treatment at the right time.
Leading The Way to Cures
It is a historic time at LLS with 18 new treatments for blood cancer approved by the Food and Drug Administration (FDA), 15 of which were supported by LLS and our generous donors. We are also on track to having more than a dozen more therapies approved this year.
For Todd Druley, MD, PhD, of Washington University in St. Louis, LLS support has been integral to his cutting-edge work in pediatric cancer. Dr. Druley is researching the genetic underpinnings of leukemia and using these discoveries to better predict and treat the disease among children. Dr. Druley’s drive is more than professional: after losing his three-year-old cousin to AML, he is determined to expand our understanding of the disease.
LLS has committed to more than doubling our investment in pediatric cancer research over the next five years, bringing our total commitment in pediatric research to more than $20 million during this time.